Cetuximab is approved for the treatment of metastatic colorectal cancer but its response rate in KRAS, BRAF, NRAS and PIK3CA exon 20 quadruple wild-type tumors accounts for only 41%, leaving a high percentage of non-responders [12]. This evidence concerns the gene KRAS and metastatic colorectal cancer.